Valuation : Elicio Therapeutics, Inc.

Market Cap 67.28M 58.04M 54.59M 49.74M 93.53M 6.39B 94.03M 645M 251M 3.25B 253M 247M 10.77B P/E 2026 *
-1.33x
P/E 2027 * -1.18x
Enterprise Value 67.28M 58.04M 54.59M 49.74M 93.53M 6.39B 94.03M 645M 251M 3.25B 253M 247M 10.77B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
72.98%
Yield 2026 *
-
Yield 2027 * -
1 day-5.19%
1 week-14.95%
Current month-5.19%
1 month-8.57%
3 months-78.88%
6 months-80.29%
Current year-67.84%
1 week 2.55
Extreme 2.55
3.05
1 month 2.55
Extreme 2.55
3.36
Current year 2.55
Extreme 2.55
16
1 year 2.55
Extreme 2.55
16
3 years 2.55
Extreme 2.55
16
5 years 2.55
Extreme 2.55
24.39
10 years 2.55
Extreme 2.55
24.39
Manager TitleAgeSince
Chief Executive Officer 66 2018-09-30
Director of Finance/CFO 54 2025-03-23
Chief Tech/Sci/R&D Officer - 2025-11-18
Director TitleAgeSince
Director/Board Member 66 2018-09-30
Director/Board Member 54 2023-05-31
Chairman 71 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/26 Free

Chief Technology Officer

64,643 0.3387%
7/16/26 Free

Chief Technology Officer

52,832 0.2768%
7/16/26 Free

Chief Executive Officer

186,944 0.9795%
Change 5-day change 1-year change 3-year change Capi.($)
-5.19%-14.95%-75.69%-67.59% 70.96M
+0.21%-2.69%+1.19%+17.32% 49.81B
+2.09%-0.71%+452.73%+498.77% 44.06B
-1.09%-0.41%+35.40%+15.17% 42.99B
-0.26%-4.71%+17.19%+71.67% 40.88B
-0.48%-0.84%+16.25%+49.80% 33.11B
-1.81%-5.02%+22.65%+113.24% 16.58B
-1.06%+2.87% - - 17.27B
-1.35%-3.40%+10.13%+26.34% 14.63B
-2.05%-5.14%+72.89%+34.69% 13.76B
Average -1.26%-3.31%+61.41%+84.38% 27.32B
Weighted average by Cap. -0.51%-1.88%+94.92%+120.38%

Financials

2026 *2027 *
Net sales - -
Net income -43.19M -37.26M -35.05M -31.93M -60.04M -4.1B -60.36M -414M -161M -2.09B -162M -159M -6.91B -60.71M -52.37M -49.26M -44.88M -84.39M -5.76B -84.85M -582M -227M -2.93B -228M -223M -9.72B
Net Debt - -
Logo Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Employees
33
Date Price Change Volume
26-09-01 US$2.560 -5.19% 334,391
26-08-31 US$2.700 -4.93% 412,186
26-08-28 US$2.840 -5.33% 421,562
26-08-27 US$3.000 +0.67% 131,240
26-08-26 US$2.980 -1.00% 182,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.560USD
Average target price
16.50USD
Spread / Average Target
+544.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELTX Stock